Targeted cancer therapy with the use of monoclonal antibodies (MABs) is a promising and ever-growing field. The addition of MAB agents to pediatric treatment regimens for patients with hematologic and oncologic diseases has greatly improved outcomes for this vulnerable population.
New MABs are being introduced regularly, and it can become an overwhelming task for the pediatric oncology nurse to accurately recall the intended aim and mechanism of action of each new MAB. In this presentation, we will review the mechanism of action of MABs, types of MABs, the use of specific MABs by disease, side effects of MABs, and nursing implications when caring for patients receiving MABs. We will discuss, in detail, the MABs commonly used in the field of pediatric hematology/oncology, including dinutuximab, rituximab, blinatumomab, inotuzumab, crizanlizumab, bevacizumab, tocilizumab, nivolumab, emicizumab, and daratumumab.
- Paper Presentation: Supportive Care/Quality Improvement — Beyond Words: Expressing Hope Through Creative Art Among Adolescents Who Have Advanced Cancer (216-3)
- Stopping the Flow: Management of Heavy Menstrual Bleeding and Menstrual Concerns in Adolescent Females with Bleeding and Clotting Disorders (226)
- General Session: Promoting Resilience in Children with Cancer and their Families (103)
- Navigating Ethics in Real World Pediatric Hematology/Oncology Nursing Practice (224)
- No Easy Target! What’s new in AML Therapy? (225)